ELA international is giving a voice to the parents of sick children who are speaking out against the planned discontinuation of a treatment currently under trial Scheduled discontinuation in 2024 In 2012, Takeda launched a clinical trial to evaluate the efficacy of an enzyme replacement therapy (TAK-611) in metachromatic leukodystrophyRead More →

A rare and devastating genetic disease Metachromatic leukodystrophy (MLD) is a rare genetic disease, occurring at a rate of 1 in 45,000 births. It can begin in childhood, adolescence, or adulthood, and leads to severe neurological dysfunction affecting motor skills and cognitive functions, and potentially to death. Libmeldy: an innovativeRead More →

ELA international repeats the ELA Families/Researchers meeting virtually, an event open to the international community of patients affected by leukodystrophy. A simultaneous translation in 5 languages (German, English, Spanish, French, Italian) allowed everyone to follow the presentations live.  The videos of the meeting are available. You can review it now:Read More →

ELA International, partner of NG4Leuko’s program led by Vivi Heine, professor of neuroscience at the University of Amsterdam, organized a review meeting in Paris which brought together 5 teams of European researchers involved in the project. After a convivial diner organized in a typical Parisian brasserie on Thursday, researchers hadRead More →

Following the symposium organized by ELA International in September 2022 on “Therapeutic Innovation: what rules and access?”, ELA International decided to set up a research ethics committee. This committee brings together 11 experts in ethics, law, human sciences, representatives of ELA families, and scientists, to promote a collegial and multidisciplinaryRead More →

Since its creation in 1992, ELA has forged special ties with Nathalie Cartier and has strongly supported her work. She participated in several events to support the actions of ELA and was a member of the Scientific Committee of ELA International from 2018 to 2022. At a time when geneRead More →